glp-1 and glp-2 drugs medication its types Emerging research suggests that GLP-1

Clin Endocrinol (Oxf) 2017

The share who report ever taking these drugs rises to four in ten (43%) among adults who have been told by a doctor that they have diabetes, a quarter who have been told they have heart disease, and one in five (22%) who have been told by a doctor that they are overweight or obese in the past five years 1

Psychological factors, including unfulfilled expectations and identity changes after marked weight loss, compound these risks [29]

Between 2021 and 2026, GLP-1 prescriptions for weight loss quadrupled from just under 3% to nearly 13%, according to Epic Research

A recent meta-analysis performed on patients with T2DM showed that all GLP-1 dose groups had a significantly higher incidence of vomiting compared to both placebo and conventional therapy, especially in individuals treated with exenatide [51]